<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67104">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01861639</url>
  </required_header>
  <id_info>
    <org_study_id>WP1P003</org_study_id>
    <nct_id>NCT01861639</nct_id>
  </id_info>
  <brief_title>Stability of rTMS on Cognition and Brain Networks on Healthy Subjects.</brief_title>
  <official_title>Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cognition and Brain Networks in Healthy Subjects in 2 Sessions 15 Days Apart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qualissima</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qualissima</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Episodic and working memory processes are the most affected cognitive domains in Alzheimer's
      Disease (AD) and its early stage, Mild Cognitive Impairment (MCI).

      Transcranial Magnetic Stimulation (TMS) is a unique tool to interfere with cognitive
      processes by inducing &quot;virtual and transient lesions&quot;, mimicking those observed in MCI. It
      has proven repeatedly its capacity to interfere with encoding-retrieval memory task.
      However, to date, only few imaging data exist on the cerebral pathways involved in encoding
      memory task. Moreover, the stability of TMS effects over time remains to be investigated. If
      proven to be a stable interfering challenge, TMS could be used to investigate the potential
      restoring effect of new medication in AD.

      The study is the pilot study of a larger clinical trial which aims to prove the utility of
      rTMS as a potential model for prediction of clinical efficacy using a combination of
      cognitive and neuroimaging endpoints.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Outputs of the memory task</measure>
    <time_frame>up to Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>outputs:  number of correct answers during the retrieval event-related task (Hit rate) and the rate of false recognition of novel pictures (False Alarms rate).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CANTAB task</measure>
    <time_frame>Day 1 and  Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>CANTAB / Rapid Visual Information Processing (RVIP)
CANTAB / Spatial Working Memory (SWM)
CANTAB / Paired Associates Learning (PAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Interest genes expression will be investigated depending on the impact of TMS on behavioral and functional brain responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging</measure>
    <time_frame>Day1 and Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional MRI (Barcelona): modifications will be highlighted by changes in Blood Oxydation level Dependence (BOLD)signal patterns
EEG (Marseille): modifications will be highlighted by changes in EEG markers</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">101</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ineffective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ineffective rTMS - Sham TBS - fMRI</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effective rTMS - Sham TBS - fMRI</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ineffective rTMS - Active TBS - EEG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effective rTMS - Active TBS - EEG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ineffective rTMS - Sham TBS - EEG</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effective rTMS - Sham TBS - EEG</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ineffective rTMS</intervention_name>
    <description>A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.</description>
    <arm_group_label>ineffective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_label>ineffective rTMS - Sham TBS - fMRI</arm_group_label>
    <arm_group_label>ineffective rTMS - Active TBS - EEG</arm_group_label>
    <arm_group_label>ineffective rTMS - Sham TBS - EEG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active TBS</intervention_name>
    <description>A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec</description>
    <arm_group_label>ineffective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_label>Effective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_label>ineffective rTMS - Active TBS - EEG</arm_group_label>
    <arm_group_label>Effective rTMS - Active TBS - EEG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham TBS</intervention_name>
    <description>A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.</description>
    <arm_group_label>ineffective rTMS - Sham TBS - fMRI</arm_group_label>
    <arm_group_label>Effective rTMS - Sham TBS - fMRI</arm_group_label>
    <arm_group_label>ineffective rTMS - Sham TBS - EEG</arm_group_label>
    <arm_group_label>Effective rTMS - Sham TBS - EEG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fMRI</intervention_name>
    <description>Functional MRI data will be acquired  during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2*-weighted echo-planar imaging sequence</description>
    <arm_group_label>ineffective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_label>Effective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_label>ineffective rTMS - Sham TBS - fMRI</arm_group_label>
    <arm_group_label>Effective rTMS - Sham TBS - fMRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EEG</intervention_name>
    <description>EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.</description>
    <arm_group_label>ineffective rTMS - Active TBS - EEG</arm_group_label>
    <arm_group_label>Effective rTMS - Active TBS - EEG</arm_group_label>
    <arm_group_label>ineffective rTMS - Sham TBS - EEG</arm_group_label>
    <arm_group_label>Effective rTMS - Sham TBS - EEG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Effective rTMS</intervention_name>
    <description>A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.</description>
    <arm_group_label>Effective rTMS - Active TBS - fMRI</arm_group_label>
    <arm_group_label>Effective rTMS - Sham TBS - fMRI</arm_group_label>
    <arm_group_label>Effective rTMS - Active TBS - EEG</arm_group_label>
    <arm_group_label>Effective rTMS - Sham TBS - EEG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged between 18 and 40 years-old inclusive.

          -  Education level: at least secondary.

          -  Right-handed (Edinburgh Handedness Inventory).

          -  The subjects are in good health on the basis of the medical interview (medical
             history, symptoms), the physical examination and vital signs.

          -  No history of psychiatric disorders (assessed by Structured Clinical Interview for
             DSM IV Disorders (SCID) for Barcelona and by the Mini International Neuropsychiatric
             Interview (MINI) for Marseille).

          -  No history of neurological disorders

          -  No history of concussion (cranial or facial trauma) without or with loss of
             consciousness.

          -  Subject without history of brain disease (severe brain trauma, stroke, cerebral
             tumor...).

          -  Subject without lesion on MRI.

          -  Subject without abnormal electrical activities on standard clinical EEG.

          -  No history of drug or alcohol abuse.

          -  No smoker or ≤ 5 cg/ day.

          -  The subject can complete the neuropsychological test battery during the training
             session.

          -  Subject without contraindication to MRI.

          -  The subject is able to read and understand the Information Form and comply with the
             protocol instructions and restrictions.

          -  The subject is covered by a social insurance.

          -  The subject has provided written informed consent.

        Exclusion Criteria:

          -  History or presence of psychiatric illness (Psychiatric interview).

          -  History or presence of neurologic illness.

          -  The subject, in the opinion of the investigator, is unlikely to comply with the study
             protocol or is unsuitable for any other reason.

          -  The subject participates in another clinical trial or is still being within a washout
             period of 1 month since last taking of a previous clinical trial, or subjects who
             have received more than 4500 Euros in the previous 12 months for participating in
             clinical trials.

          -  Presence of metallic objects within the body.

          -  Subjects with pacemaker.

          -  Claustrophobia.

          -  Individual and familial history of epileptic seizure.

          -  Any medication listed (see annexe) in the safety guidelines published by the Safety
             of TMS Consensus Group (Rossi et al., 2009) will be forbidden.

          -  Subject with a correct hit rate during the retrieval session of the memory task
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bartrés-Faz</last_name>
    <role>Principal Investigator</role>
    <affiliation>IDIBAPS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Audebert</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC-CPCET</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cic-Cpcet</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Audebert</last_name>
      <phone>+33 491 387 563</phone>
      <email>christine.audebert@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Audebert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IDIBAPS</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bartrés-Faz</last_name>
      <phone>+34 93 403 92 97</phone>
      <email>dbartres@ub.edu</email>
    </contact>
    <investigator>
      <last_name>David Bartrés-Faz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
